We are live on ! Find out more
PS

Peter Svennilson Portfolio holdings

AUM $1.23B
1-Year Est. Return 301.34%
This Fund
S&P 500
This Quarter Est. Return
+39.33%
1 Year Est. Return
+301.34%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.2B
AUM Growth
+$406M
Cap. Flow
+$102M
Cap. Flow %
8.55%
Top 10 Hldgs %
100%
Holding
7
New
1
Increased
1
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
ORIC icon
Oric Pharmaceuticals
ORIC
+$152M
2
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
+$7.34M

Top Sells

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$47.9M
2
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$9.44M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NGM
1
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$350M 29.23%
17,706,978
+383,834
+2% +$7.34M
RVMD icon
2
Revolution Medicines
RVMD
$39.9B
$252M 21.06%
7,977,384
– –
RAPT
3
DELISTED
RAPT Therapeutics
RAPT
$197M 16.45%
847,144
– –
CNST
4
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$182M 15.21%
6,051,376
– –
ORIC icon
5
Oric Pharmaceuticals
ORIC
$1.15B
$161M 13.45%
+4,768,181
New +$152M
RCUS icon
6
Arcus Biosciences
RCUS
$3.55B
$43.7M 3.66%
1,767,676
-1,773,174
-50% -$47.9M
GRTS
7
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$11.3M 0.94%
1,700,945
-1,401,989
-45% -$9.44M

Similar funds

CT
CGM Trust Boston, Massachusetts $957M AUM
CAW
Cornerstone Advisors (Washington) Bellevue, Washington $936M AUM 8.77% 1-Year Est. Return
VIM
Veritas Investment Management London, United Kingdom $1.65B AUM 25.54% 1-Year Est. Return
SFSG
Stearns Financial Services Group Greensboro, North Carolina $639M AUM 11.66% 1-Year Est. Return
KFA
Kays Financial Advisory Atlanta, Georgia $624M AUM 9.93% 1-Year Est. Return
11A
10-15 Associates Goshen, New York $516M AUM 7.62% 1-Year Est. Return
TI
TT International London, United Kingdom $1.94B AUM
IA
Independence Advisors Wayne, Pennsylvania $466M AUM 11.32% 1-Year Est. Return

Peter Svennilson's Q2 2020 Portfolio in Review

As of Q2 2020, Peter Svennilson held 7 positions worth $1.2B, up 51% from $790M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Peter Svennilson deployed $102M of net new capital in Q2 2020, opening 1 new position and adding to 1 existing holding. Its largest new stake was Oric Pharmaceuticals: 4,768,181 shares worth $161M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Arcus Biosciences, an estimated $47.9M trimmed.

  • Peter Svennilson's largest Q2 2020 buy was Oric Pharmaceuticals: 4,768,181 shares worth $161M.
  • Peter Svennilson added most to NGM Biopharmaceuticals, Inc. Common Stock in Q2 2020, an estimated $7.34M increase.
  • Peter Svennilson's biggest Q2 2020 reduction was Arcus Biosciences, cutting an estimated $47.9M.
  • Peter Svennilson's ten largest holdings make up 100% of its $1.2B portfolio in Q2 2020.
  • Peter Svennilson opened 1 new position and closed 0 in Q2 2020.
  • Peter Svennilson's portfolio value rose 51% quarter-over-quarter to $1.2B.

Based on Peter Svennilson's 13F filing for Q2 2020, filed 12 Aug 2020.